News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingKey Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article from Investing.com is a brief notice about Coya Therapeutics Inc.'s Form 8K filing for August 11. It simply states that the Form 8K has been published and provides no further details about the content of the filing. The article also includes stock …
Coya Therapeutics presented an investor update on its Treg-directed combination therapy for neurodegenerative diseases, highlighting COYA 302 as its lead program. An ALS Phase 2 readout is anticipated in Q1 2027, with enrollment for the ALSTARS Phase 2 trial expected to conclude in H2 …
Coya Therapeutics announced its Q2 2026 financial results, highlighting progress on its lead program, COYA 302, for ALS and frontotemporal dementia. The company received FDA Fast Track Designation for COYA 302 in ALS and expects to complete Phase 2 enrollment for the ALSTARS ALS …
Coya Therapeutics reported a Q2 net loss of $6.6 million, an increase from $6.1 million in the prior year, with a net loss per share of $0.28. The company ended the quarter with $43.2 million in cash, sufficient to fund operations past its Phase …
Coya Therapeutics, Inc. announced the appointment of Mark H. Pavao to its Audit Committee of the Board, effective August 6, 2026. This appointment was made upon the recommendation of the Nominating and Corporate Governance Committee. Following this change, the Audit Committee now includes Dr. …
Coya Therapeutics (NASDAQ: COYA) has announced the appointment of Mark H. Pavao to its Audit Committee, effective immediately. This follows his prior appointment to the Board of Directors on April 1, 2026, which was initially disclosed without committee assignments. The Audit Committee now includes …
Coya Therapeutics Inc (COYA) has an earnings forecast score of 8.33, ranking 138th in its industry. Analysts have set an average price target of $16.00 for COYA, with most supporting a "Buy" trend. The company's expected revenue for the next quarter is $100,000, and …
This article highlights bullish analyst ratings for several healthcare stocks, including Stoke Therapeutics (STOK), Fortrea Holdings Inc. (FTRE), and SI-Bone (SIBN). Analysts from Chardan Capital and TD Cowen reiterated Buy ratings for these companies, providing specific price targets and noting potential upsides. The report …
Coya Therapeutics Inc (COYA) has a current financial score of 6.42, placing it 245th out of 384 in the Biotechnology & Medical Research industry, indicating a robust financial status but low operating efficiency. The company's latest quarterly revenue decreased by 2.61% year-over-year to 251.15K, …
Coya Therapeutics Inc (COYA) has a current valuation score of 6.86, placing it 248th out of 385 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -3.64, which is significantly below its recent high and above its recent low. Key …
This article provides a technical analysis of Coya Therapeutics Inc (COYA), focusing on its stock price momentum, support and resistance levels, and key technical indicators and moving averages. As of July 28, 2026, Coya Therapeutics Inc's stock price momentum score is 5.14, ranking 119 …
This article provides a detailed stock analysis of Coya Therapeutics Inc (COYA) by TradingKey, assigning it a comprehensive stock score based on various financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment indicators. Despite a recent weak stock market performance, COYA …
Orin Hirschman and affiliated investment entities, including AIGH Capital Management LLC and AIGH Investment Partners LLC, have filed an amended Schedule 13G disclosing a 3.3% beneficial ownership stake in Coya Therapeutics Inc. (NASDAQ: COYA). This represents 764,679 shares of common stock, over which they …
This article provides a detailed cash flow statement for Coya Therapeutics Inc (COYA), presenting quarterly and annual data for operating, investing, and financing activities. It includes year-over-year percentage changes and absolute figures for various cash flow components. Additionally, the article offers FAQs explaining key …
Coya Therapeutics Inc (COYA) is a clinical-stage biotechnology company developing treatments targeting systemic inflammation and neuroinflammation using regulatory T cells. Despite a recent weak market performance, the company exhibits strong fundamentals, including consistent revenue growth averaging 32.38% annually over the last three years and …
This article provides an overview of Coya Therapeutics (COYA) market sentiment, including analyst consensus, short interest, options flow, and insider activity. Analysts have a "Buy" consensus with an average price target significantly higher than the current stock price. Short interest is declining, considered a …
This article details the shareholder structure of Coya Therapeutics Inc (COYA), listing major shareholders such as Greenlight Capital, Inc. and Dr Reddy's Laboratories Ltd, along with their respective proportions. It also categorizes shareholders by type and provides a historical overview of institutional shareholding changes. …
This article provides historical dividend and stock split information for Coya Therapeutics Inc (COYA). It states that the company has distributed a total of $0.00 USD in dividends over the past five years, indicating no recent dividend payouts. The page also presents current stock …
Coya Therapeutics, Inc. (NASDAQ:COYA) reported a total revenue of $7.95 million USD last year. This revenue primarily came from its Proprietary Medicinal Products segment, marking an increase from $3.55 million USD in the prior year. The United States was the sole contributor to this …
This article from Stock Traders Daily discusses the application of discipline and rules-based execution for COYA Therapeutics Inc. (NASDAQ: COYA) using AI models. It highlights three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The content emphasizes real-time signals, risk …
This article provides the "Price to book forward" value for Coya Therapeutics, Inc. (NASDAQ: COYA). While the specific value is not detailed in the provided content, the article indicates that this financial metric is available for the company on TradingView. It also lists various …
Coya Therapeutics, a Houston-based biotech, is advancing its lead candidate COYA 302 for ALS, with a pivotal Phase 2 trial readout expected in early 2027 and potential conditional approval by the first half of 2028. The company is supported by strong analyst ratings and …
Coya Therapeutics (COYA) is a clinical-stage biopharma company focusing on treatments for ALS and dementia, with multiple analysts giving "Buy" ratings and price targets up to US$18. The company anticipates a significant trial readout in Q1 2027 for its ALS drug, COYA 302, with …
Search by ticker symbol or company name and select a result to open its chart.